Ignite Creation Date:
2024-05-06 @ 9:44 AM
Last Modification Date:
2024-10-26 @ 12:18 PM
Study NCT ID:
NCT03052478
Status:
COMPLETED
Last Update Posted:
2021-06-08
First Post:
2017-02-10
Brief Title:
Study of Vismodegib in Advanced Gastric Adenocarcinoma Patients With SMO Overexpression
Sponsor:
Samsung Medical Center
Organization:
Samsung Medical Center
Study Overview
Official Title:
Phase II Single-arm Study of Vismodegib in Advanced Gastric Adenocarcinoma Patients With SMO Overexpression
Status:
COMPLETED
Status Verified Date:
2021-06
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
There is no accepted standard therapy for patients with advanced gastric cancer who have progressed during or after second-line therapy The role of 3rd line treatment in advanced gastric cancer has not been proven
As a novel target of gastric cancer SMO overexpression is chosen in this study and the investigators plan this study to evaluate the efficacy and safety of vismodegib in gastric cancer The doses of vismodegib are based on trials of basal cell carcinoma
As a novel target of gastric cancer SMO overexpression is chosen in this study and the investigators plan this study to evaluate the efficacy and safety of vismodegib in gastric cancer The doses of vismodegib are based on trials of basal cell carcinoma
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None